RT Journal Article
T1 PLGA‑PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy
A1 González‑Melero, Lorena
A1 Santos‑Vizcaíno, Edorta
A1 Varela Calviño, Rubén
A1 Gómez Touriño, Iria María
A1 Asumendi, Aintzane
A1 Boyano, María Dolores
A1 Igartua, Manoli
A1 Hernández, Rosa María
K1 Cancer
K1 Immunotherapy
K1 Nanoparticle
K1 Neoantigen
K1 PLGA
K1 Poly(I:C)
K1 Vaccine
AB Melanoma is the main cause of death among skin cancers and its incidence worldwide has been experiencing an appalling increase. However, traditional treatments lack effectiveness in advanced or metastatic patients. Immunotherapy, meanwhile, has been shown to be an effective treatment option, but the rate of cancers responding remains far from ideal. Here we have developed a personalized neoantigen peptide-based cancer vaccine by encapsulating patient derived melanoma neoantigens in polyethylenimine (PEI)-functionalised poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) and coating them with polyinosinic:polycytidylic acid (poly(I:C)). We found that PLGA NPs can be effectively modified to be coated with the immunoadjuvant poly(I:C), as well as to encapsulate neoantigens. In addition, we found that both dendritic cells (DCs) and lymphocytes were effectively stimulated. Moreover, the developed NP was found to have a better immune activation profile than NP without poly(I:C) or without antigen. Our results demonstrate that the developed vaccine has a high capacity to activate the immune system, efficiently maturing DCs to present the antigen of choice and promoting the activity of lymphocytes to exert their cytotoxic function. Therefore, the immune response generated is optimal and specific for the elimination of melanoma tumour cells.
PB Springer Nature
SN 2190-393X
YR 2024
FD 2024-03-01
LK https://hdl.handle.net/10347/38953
UL https://hdl.handle.net/10347/38953
LA eng
NO Gonzalez-Melero, L., Santos-Vizcaino, E., Varela-Calvino, R., Gomez-Tourino, I., Asumendi, A., Boyano, M. D., Igartua, M., & Hernandez, R. M. (2024). PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy. Drug Delivery and Translational Research, 14(10), 2788–2803. https://doi.org/10.1007/s13346-024-01557-2
NO CRUE-CSIC
DS Minerva
RD 22 abr 2026